oxindanac has been researched along with Cholera Infantum in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aabakken, L; Axelsson, CK; Szecsi, PB | 1 |
| Aabakken, L; Dybdahl, JH; Eidsaunet, W; Haaland, A; Larsen, S; Osnes, M | 1 |
2 trial(s) available for oxindanac and Cholera Infantum
| Article | Year |
|---|---|
Pepsinogen A and C serum levels in relation to acute NSAID-associated mucosal lesions in healthy volunteers.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Double-Blind Method; Duodenum; Gastric Mucosa; Gastrointestinal Diseases; Humans; Indenes; Intestinal Mucosa; Male; Naproxen; Pepsinogens; Piroxicam | 1993 |
Optimal assessment of gastrointestinal side effects induced by non-steroidal anti-inflammatory drugs. Endoscopic lesions, faecal blood loss, and symptoms not necessarily correlated, as observed after naproxen and oxindanac in healthy volunteers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; Duodenoscopy; Gastric Mucosa; Gastrointestinal Diseases; Gastroscopy; Humans; Indenes; Intestinal Mucosa; Male; Naproxen; Occult Blood; Random Allocation | 1989 |